Assessment of cardiac safety for PPARγ agonists in rodent models of heart failure: A translational medicine perspective

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 264-271

  Wang, Xinkang ^a  

^a AGENNIX INC   (United States)

Author keywords

Animal models; Biomarker; Cardiac safety; Heart failure; PPAR; Rosiglitazone; Translational; TZD

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; POTASSIUM CHANNEL; RENAL OUTER MEDULLARY POTASSIUM CHANNEL 1; ROSIGLITAZONE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CELL INFILTRATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ECHOCARDIOGRAPHY; FLUID RETENTION; GENE EXPRESSION PROFILING; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE ISCHEMIA; HEART PACING; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEMATOCRIT; INFLAMMATION; KIDNEY DISEASE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHARMACOGENOMICS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHAM PROCEDURE; TRANSLATIONAL RESEARCH; WEIGHT GAIN; ZUCKER RAT;

EID: 84861720586     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020264     Document Type: Review

References (34)

1. Bensinger, S.J.; Tontonoz, P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature, 2008, 454, 470-477
2. Duan, S.Z.; Usher, M.G.; Mortensen, R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ. Res., 2008, 102, 283-294.
3. Krentz, A. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes Metab. Res. Rev., 2009, 25, 112-126.
4. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356, 2457-2471.
5. Hernandez, A.V.; Usmani, A.; Rajamanickam, A.; Moheet, A. Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials. Am. J. Cardiovasc. Drugs, 2011, 11, 115-128.
6. Lago, R.M.; Singh, P.P.; Nesto, R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet, 2007, 370, 1129-1136.
7. Robinson, J.G. Should We Use PPAR Agonists to Reduce Cardiovascular Risk? PPAR Res, 2008, 891425.
8. Erdmann, E.; Charbonnel, B.; Wilcox, R. Thiazolidinediones and cardiovascular risk-a question of balance. Curr. Cardiol. Rev., 2009, 5, 155-165.
9. Woodcock, J.; Sharfstein, J.M.; Hamburg, M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N. Engl. J. Med., 2010, 363, 1489-1491.
10. Buckingham, R.E.; Hanna, A. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Diabetes Obes. Metab., 2008, 10, 312-328.
11. Duan, S.Z.; Ivashchenko, C.Y.; Russell, M.W.; Milstone, D.S.; Mortensen, R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ. Res., 2005, 97, 372-379.
12. Haddad, F.; Doyle, R.; Murphy, D.J.; Hunt, S.A. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation, 2008, 117, 1717-1731.
13. Elsner, D.; Riegger, G.A. Characteristics and clinical relevance of animal models of heart failure. Curr. Opin. Cardiol., 1995, 10, 253-259.
14. Yue, T.L.; Chen, J.; Bao, W.; Narayanan, P.K.; Bril, A.; Jiang, W.; Lysko, P.G.; Gu, J.L.; Boyce, R.; Zimmerman, D.M.; Hart, T.K.; Buckingham, R.E.; Ohlstein, E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferatoractivated receptor-gamma agonist rosiglitazone. Circulation, 2001, 104, 2588-2594.
15. Sidell, R.J.; Cole, M.A.; Draper, N.J.; Desrois, M.; Buckingham, R.E.; Clarke, K. Thiozolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes, 2002, 51, 1110-1117.
16. 2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes, 2002, 51, 1507-1514.
17. Johns, D.G.; Ao, Z.; Eybye, M.; Olzinski, A.; Costell, M.; Gruver, S.; Smith, S.A.; Douglas, S.A.; Macphee, C.H. Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat. J. Pharmacol. Exp. Ther., 2005, 315, 1020-1027.
18. Mersmann, J.; Tran, N.; Zacharowski, P.A.; Grotemeyer, D.; Zacharowski, K. Rosiglitazone is cardioprotective in a murine model of myocardial I/R. Shock, 2008, 30, 64-68.
19. Shiomi, T.; Tsutsui, H.; Hayashidani, S.; Suematsu, N.; Ikeuchi, M.; Wen, J.; Ishibashi, M.; Kubota, T.; Egashira, K.; Takeshita, A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002, 106, 3126-3132.
20. Frantz, S.; Hu, K.; Widder, J.; Bayer, B.; Witzel, C.C.; Schmidt, I.; Galuppo, P.; Strotmann, J.; Ertl, G.; Bauersachs, J. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br. J. Pharmacol., 2004, 141, 9-14.
21. Lygate, C.A.; Hulbert, K.; Monfared, M.; Cole, M.A.; Clarke, K.; Neubauer, S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc. Res., 2003, 58, 632-637.
22. Lee, H.H.; Yeh, C.H.; Chen, Y.T.; Chi, T.C.; Cheng, J.T.; Lo, S.H. Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice. Biol. Pharm. Bull., 2010, 33, 1506-1510.
23. Wang, X.; Liu, X.; Zhan, Y.; Lavallie, E.R.; Diblasio-Smith, L.; Collins-Racie, L.; Mounts, W.M.; Rutkowski, J.L.; Xu, X.; Goltsman, I.; Abassi, Z.; Winaver, J.; Feuerstein, G.Z. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation. J. Pharmacol. Exp. Ther., 2010, 334, 820-829.
24. Vasan, R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006, 113, 2335-2362.
25. Walker, D.B. Serum chemical biomarkers of cardiac injury for nonclinical safety testing. Toxicol. Pathol., 2006, 34, 94-104.
26. Marrer, E.; Dieterle, F. Impact of biomarker development on drug safety assessment. Toxicol. Appl. Pharmacol., 2010, 243, 167-179.
27. Wang, X.; Connolly, T.M. Biomarkers of vulnerable atheromatous plaques: translational medicine perspectives. Adv. Clin. Chem., 2010, 50, 1-22.
28. Lindenfeld, J.; Masoudi, F.A. Fluid retention with thiazolidinediones: does the mechanism influence the outcome? J. Am. Coll. Cardiol., 2007, 49, 1705-1707.
29. Leong, D.P.; De Pasquale, C.G.; Selvanayagam, J.B. Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging. JACC Cardiovasc. Imaging, 2010, 3, 409-420.
30. Shetty, S.; Kusminski, C.M.; Scherer, P.E. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol. Sci., 2009, 30, 234-239.
31. Zhang, H.; Zhang, A.; Kohan, D.E.; Nelson, R.D.; Gonzalez, F.J.; Yang, T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedioneinduced fluid retention. Proc. Natl. Acad. Sci. USA, 2005, 102, 9406-9411.
32. Forcheron, F.; Basset, A.; Abdallah, P.; Del Carmine, P.; Gadot, N.; Beylot, M. Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat. Cardiovasc. Diabetol., 2009, 8, 16.
33. Kherani, A.R.; Moss, G.W.; Zhou, H.; Gu, A.; Zhang, G.; Schulman, A.R.; Fal, J.M.; Sorabella, R.; Plasse, T.; Rui, L.; Homma, S.; Burkhoff, D.; Oz, M.C.; Wang, J. Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure. J. Cardiovasc. Pharmacol., 2004, 44, 665-671.
34. Dubois, E.; Fertin, M.; Burdese, J.; Amouyel, P.; Bauters, C.; Pinet, F. Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular remodeling. Proteomics Clin. Appl., 2011, 5, 57-66.